Antibody-mediated rejection: New approaches in prevention and management.

about

Antibody-mediated rejection: New approaches in prevention and management.

Item

http://www.wikidata.org/entity/Q52401610

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Antibody-mediated rejection: New approaches in prevention and management.

@en

Antibody-mediated rejection: New approaches in prevention and management.

@nl

type

Item

label

Antibody-mediated rejection: New approaches in prevention and management.

@en

Antibody-mediated rejection: New approaches in prevention and management.

@nl

prefLabel

Antibody-mediated rejection: New approaches in prevention and management.

@en

Antibody-mediated rejection: New approaches in prevention and management.

@nl

P1476

Antibody-mediated rejection: New approaches in prevention and management.

@en

P2093

A Loupy

http://www.w3.org/2001/XMLSchema#string

D L Segev

http://www.w3.org/2001/XMLSchema#string

R A Montgomery

http://www.w3.org/2001/XMLSchema#string

P2860

The Complement System and Antibody-Mediated Transplant Rejection

Eculizumab and renal transplantation in a patient with CAPS

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

P304

3-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.14584

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

18 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29292861

http://www.w3.org/2001/XMLSchema#string